Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
3
×
life sciences
3
×
national blog main
biotech
clinical trials
san francisco
san francisco blog main
san francisco top stories
biotech ipos
boston
boston blog main
boston top stories
cannabidiol
deals
dravet syndrome
drugs
dyne therapeutics
epidiolex
fen-phen
fenfluramine
food and drug administration
gw pharmaceuticals
lennox-gastaut syndrome
medical device
metacrine
myotonic dystrophy type 1
nonalcoholic steatohepatitis
pulmonary arterial hypertension
raleigh-durham blog main
rare disease drugs
rare diseases
salk institute
san diego blog main
san diego top stories
startups
steadymed
treprostinil
ulcerative colitis
united therapeutics
zogenix
What
drug
rare
3
×
therapeutics
ago
approved
battle
brings
building
cannabis
company
data
deal
derivative
developer
developing
disease
disorders
dyne
dyne’s
epilepsy
established
fda
firm
form
genetic
gw
gw’s
ipo
lung
marijuana
market
medicine
medicines
million
momentum
muscle
muscular
pah
pharmaceuticals
preclinical
Language
unset
Current search:
rare
×
fda
×
" life sciences "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
